The British National Formulary is the unrivalled guidance on prescribing, dispensing and administering medicines.
The BNF is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. It is trusted by health professionals worldwide as their primary source for minimising medication errors.
SubscribeContent Updates
Speed and safety: Provides rapid reference to essential information on the selection of safe and effective medicines for individual patients
Evidence Grading: As part of NICE accreditation recommendations, BNF content is now evidence graded to reflect the strength of evidence behind them, increasing transparency to support healthcare professionals with clinical decision making
Always up-to-date: The content is revalidated, revised, and updated on a monthly basis, making sure you have access to the very latest prescribing knowledge
Worldwide credibility: The BNF uses clinical evidence from a diverse range of sources and a network of experts, giving you the confidence to select medicines safely
*based on average data in the last 12 months
This update contains 7 significant changes, 2 dose changes and 8 new preparations.
Significant Changes:
Dose Changes:
New Preparations:
For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm
This update contains 12 significant changes, 3 dose changes and 5 new preparations.
Significant Changes:
• Baricitinib (Olumiant®): risk of venous thromboembolism [MHRA/CHM advice].
• Benzodiazepines: reminder of risk of potentially fatal respiratory depression [MHRA/CHM advice] (advice in alprazolam, chlordiazepoxide hydrochloride, clobazam, clonazepam, diazepam, flurazepam, loprazolam, lorazepam, lormetazepam, midazolam, nitrazepam, oxazepam, temazepam; see example in diazepam).
• Canagliflozin (SGLT2 inhibitors): monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness [MHRA/CHM advice].
• COVID-19: new guidance incorporating a collection of resources.
• Dapagliflozin (SGLT2 inhibitors): monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness [MHRA/CHM advice].
• Empagliflozin (SGLT2 inhibitors): monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness [MHRA/CHM advice].
• Ertugliflozin (SGLT2 inhibitors): monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness [MHRA/CHM advice].
• Opioids: reminder of risk of potentially fatal respiratory depression [MHRA/CHM advice] (advice in alfentanil, buprenorphine, codeine phosphate, diamorphine hydrochloride, dihydrocodeine tartrate, dipipanone hydrochloride, fentanyl, hydromorphone hydrochloride, meptazinol, methadone hydrochloride, morphine, oxycodone hydrochloride, pentazocine, pethidine hydrochloride, remifentanil, sufentanil, tapentadol, tramadol hydrochloride; see example in morphine).
• Skin infections, antibacterial therapy: new guidance for management of leg ulcer infection.
• Tofacitinib (Xeljanz®): new measures to minimise risk of venous thromboembolism and of serious and fatal infections [MHRA/CHM advice].
• Ulipristal acetate (Esmya®): suspension of the licence due to risk of serious liver injury [MHRA/CHM advice].
• Upadacitinib (Rinvoq®▼): advice for venous thromboembolism [MHRA/CHM advice].
Dose Changes:
• Betamethasone with clioquinol [updated child age range].
• Glucagon [update to age ranges for hypoglycaemia].
• Sodium fluoride [updating dosing for prophylaxis of dental caries].
New Preparations: Cytotect® [cytomegalovirus immunoglobulin], Evenity® [romosozumab], Polivy® [polatuzumab vedotin], Poteligeo® [mogamulizumab], Ultomiris® [ravulizumab].
For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm
This update contains 13 significant changes, 5 dose changes and 2 new preparations.
Significant Changes:
• Adrenaline/epinephrine (Emerade®) pre-filled auto-injector: update on failure to activate [MHRA/CHM advice].
• Alemtuzumab (Lemtrada®): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions [MHRA/CHM advice].
• Antimicrobial stewardship: new guidance.
• Cardiovascular disease risk assessment and prevention: updated guidance.
• Dapagliflozin with insulin for treating type 1 diabetes [NICE guidance].
• Diverticular disease and diverticulitis: updated guidance on management.
• Etonogestrel (Nexplanon®) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury and implant migration [MHRA/CHM advice].
• Gastro-intestinal system infections, antibacterial therapy: updated guidance for acute diverticulitis.
• Ingenol mebutate gel (Picato®): suspension of the licence due to risk of skin malignancy [MHRA/CHM advice].
• Medicines optimisation: new guidance.
• Modafinil: potential risk of congenital malformations during pregnancy [MHRA/CHM advice].
• Patiromer calcium for treating hyperkalaemia [NICE guidance].
• Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis [NICE guidance].
Dose Changes:
• Benzoin tincture, compound [updated child age range].
• Ergotamine tartrate with caffeine hydrate and cyclizine hydrochloride [addition of max. courses per month].
• Eucalyptus with menthol [frequency of dosing].
• Fluocinolone acetonide with clioquinol [updated dosing frequency].
• Paracetamol with buclizine hydrochloride and codeine phosphate [child age ranges].
New Preparations:
Benzathine benzylpenicillin, Mayzent® [ siponimod ].
For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm
This update contains 13 significant changes and 3 new preparations.
Significant Changes:
• Cannabidiol with clobazam for treating seizures associated with Dravet syndrome [NICE guidance].
• Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome [NICE guidance].
• Diabetic foot infections, antibacterial therapy: new guidance on management.
• Malaria, prophylaxis: updated country recommendations in the recommended regimens for prophylaxis against malaria in-line with Public Health England.
• Malaria, prophylaxis: updated guidance in-line with Public Health England recommendations.
• Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [NICE guidance].
• Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy [MHRA/CHM advice].
• Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer [NICE guidance].
• Pain, Chronic: new guidance on management.
• Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer [NICE guidance].
• Pneumococcal vaccine: updated guidance in-line with Public Health England recommendations.
• Sodium valproate: updated Pregnancy Prevention Programme [MHRA/CHM advice].
• Valproic acid: updated Pregnancy Prevention Programme [MHRA/CHM advice].
New Preparations: Aritso® [strontium ranelate], Rinvoq® [upadacitinib], Zalkya® [dienogest].
For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm
This update contains 9 significant changes, 1 dose change and 1 new preparation.
Significant Changes
Dose Changes
New Preparations
For further details on changes in the BNF click on
http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm
This update contains 12 significant changes and 5 new preparations.
Significant Changes:
New Preparations: Nerlynx® [neratinib], Pepto-Bismol® [bismuth subsalicylate], Softacort® [hydrocortisone eye drops], Vaborem® [meropenem with vaborbactam], Xospata® [gilteritinib].
For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm
